Overview

This trial is active, not recruiting.

Conditions cardiovascular diseases, heart diseases, myocardial infarction, coronary disease, arrhythmia, ventricular fibrillation
Treatments beta adrenergic blockers, platelet inhibitors, ace inhibitors, ptca and/or stents
Sponsor National Heart, Lung, and Blood Institute (NHLBI)
Start date September 2002
Trial size 300 participants
Trial identifier NCT00119847, 221, R01 HL72906

Summary

The purpose of this study is to determine if opening blocked arteries with heart balloons and stents prevents heart rhythm problems in individuals 3 to 28 days after a heart attack.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification efficacy study
Primary purpose treatment

Primary Outcomes

Measure
Short-termed fractal scaling exponent (alpha 1) (measured at Year 1)
time frame:

Secondary Outcomes

Measure
Temporal variability in time
time frame:
Temporal variability in amplitude
time frame:
Filtered QRS duration
time frame:
Composite OAT clinical outcome of death, heart attack, and development of class IV congestive heart failure (measured at Year 1)
time frame:

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - Has experienced a heart attack 3 to 28 days prior to study entry - Persistently occluded IRA defined as either: 1) Thrombolysis in Myocardial Infarction (TIMI) 0, with no flow beyond the site of occlusion; or 2) TIMI 1, with penetration of dye beyond the site of occlusion without dye reaching the distal vessel - LVEF less than 50% or proximal occlusion in a large vessel - Normal sinus rhythm - QRS duration less than 120 ms - Able to return for follow-up assessment of arrhythmia markers one month and one year after study entry Exclusion Criteria: - Has a clinical indication for revascularization (post-heart attack angina at rest; significant inducible ischemia; or significant left main or triple vessel disease requiring PTCA or CABG) - Current serious illness or condition that limits 3-year survival - Severe valvular disease - Chronic total occlusion - New York Heart Association Class III-IV congestive heart failure - Prior left ventricular aneurysm in the recent heart attack location - Is a poor candidate for PTCA/stent on the basis of angiographic or clinical criteria - Cannot medically survive anticoagulation during PTCA/stent or antiplatelet therapy after stent - Pregnant

Additional Information

Official title Electrophysiologic Effects of Late PCI (OAT-EP)
Description BACKGROUND: There is now unequivocal evidence that early coronary reperfusion using either thrombolytics or primary angioplasty results in a long-term mortality reduction among individuals who have had a heart attack. The benefit of early reperfusion (less than 6 hours after the heart attack) was initially attributed to myocardial salvage and the resultant preservation of left ventricular function. However, it is now known that the survival benefit associated with thrombolytic therapy is not consistently associated with a major improvement in left ventricular ejection fraction (LVEF). These observations led to the formulation of the "late open artery hypothesis," which suggests that clinical outcomes can potentially be improved by late reperfusion after a heart attack. Observational clinical studies have suggested that late patency of the infarct-related artery (IRA) after thrombolysis is associated with a survival benefit that is independent of LVEF and therefore cannot be solely explained by salvage of myocardium. Definitive proof of the late open artery hypothesis is currently lacking, however, because previous studies that have evaluated late percutaneous transluminal coronary angioplasty (PTCA) of occluded IRAs after a heart attack have produced conflicting results. These findings led to the organization of the Occluded Artery Trial (OAT), an international, NHLBI-funded, randomized trial of 2,200 participants. OAT is testing the hypothesis that mechanical reperfusion of an occluded IRA with PTCA and percutaneous coronary intervention (PCI) 3 to 28 days after a heart attack in high-risk individuals will reduce mortality, recurrent heart attacks, and hospitalization for class IV congestive heart failure. Enhancement of electrical stability is one of the major mechanisms that has been proposed to explain the association of an open IRA with an improved prognosis independent of myocardial salvage. DESIGN NARRATIVE: This study is an ancillary study of OAT. It will characterize the effects of late PCI of occluded IRAs on the most important and clinically relevant noninvasive markers of vulnerability to malignant ventricular arrhythmias: heart rate variability, T wave variability, and signal-averaged electrocardiography. These analyses will be performed in 300 participants at baseline, 30 days, and 1 year following a heart attack in order to determine the effects of late PCI on the autonomic nervous system, ventricular repolarization, and ventricular conduction abnormalities.
Trial information was received from ClinicalTrials.gov and was last updated in February 2006.
Information provided to ClinicalTrials.gov by National Heart, Lung, and Blood Institute (NHLBI).